Source: Eur Respir J 2008; 32: 113-120
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
Lefebvre, B., Pepin, J-L., Baguet, J-P., Tamisier, R., Roustit, M., Riedweg, K., Bessard, G., Levy, P., Stanke-Labesque, F.. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea?. Eur Respir J 2008; 32: 113-120

Member's Comments

No comment yet.

Related content which might interest you: 5-lipoxygenase pathway: one of the mediators of early atherosclerosis in obstructive sleep apnea syndrome? Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007 Leukotriene B4 as an early predictor of carotid atherosclerosis in patients with obstructive sleep apnea Source: International Congress 2014 – The story continues: impact of OSA on cardiometabolic parameters Year: 2014 Expression of cysteinyl leukotriene receptors in tonsillar T and B lymphocytes of children with obstructive sleep apnea Source: Annual Congress 2011 - Obstructive sleep apnoea: inflammation and metabolism Year: 2011 Pathogenic role of angiotensin II and oxidised LDL in obstructive sleep apnoea Source: Eur Respir J 2009; 34: 1390-1398 Year: 2009 Circulating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoea Source: Eur Respir J 2009; 33: 574-580 Year: 2009 Systemic and airway inflammation in sleep apnea and obesity: the role of ICAM-1 and IL-8 Source: Annual Congress 2008 - Basic science in asthma and COPD Year: 2008 Serum leukotriene B4 levels, tonsillar hypertrophy and obstructive sleep-disordered breathing in childhood Source: International Congress 2015 – Monitoring sleep-disordered breathing in children and adults Year: 2015 Lipoprotein-associated phospholipase A2 levels as a predictor of cardiovascular risks in patients with COPD and obstructive sleep apnea Source: Annual Congress 2013 –Of mice and men: sleep disordered breathing Year: 2013 Local airway inflammation in obstructive sleep apnoea: the role of leptin Source: Eur Respir J 2006; 28: Suppl. 50, 645s Year: 2006 Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation Source: Eur Respir J 2009; 33: 1195-1205 Year: 2009 Obstructive sleep apnoea and COPD Source: Eur Respir Mon 2013; 59: 135-143 Year: 2013 Production of TNF-α, MMPs, and MCP-1 by monocytes and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2004; 24: Suppl. 48, 331s Year: 2004 NKT cells in systemic inflammation in the obstructive sleep apnoea syndrome (OSAS) Source: International Congress 2015 – Mucosal immunology: what’s new in 2015 Year: 2015 Selective activation of pro-inflammatory cytokines in obstructive sleep apnoea syndrome and impact of CPAP Source: Eur Respir J 2005; 26: Suppl. 49, 355s Year: 2005 Is snoring the cause of oxidative stress in airways in obstructive sleep apnea patients? Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015 Pharyngeal and systemic inflammation in obstructive sleep apnea (OSA) Source: International Congress 2015 – Ring of fire: inflammation and metabolism in sleep-disordered breathing Year: 2015 Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnoea Source: Eur Respir J 2009; 33: 793-796 Year: 2009 Changes in inflammatory mediators as a result of intermittent hypoxia in obstructive sleep apnea syndrome Source: International Congress 2016 – Hypoxia, oxidative stress, and biomarkers in obstructive sleep apnoea Year: 2016 The role of pro- and anti- inflammatory cytokines in the pathogenesis of obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea Year: 2008 Inflammatory and vasoactive arachidonic acid (aa) metabolites in obstructive sleep apnea (OSA) Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009